ClinicalTrials.gg
RecruitingNCT07294274Updated Feb 5, 2026

Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke

An observational study in Post-stroke Depression, sponsored by Min Su. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Min Su · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
488
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Planned enrollment
27th of 74
488 · median 306
Started
2025
with 40 others
Observational
74 of 358
30 open now
Primary completion
2026-07
later than 65 of 137 live
Registered
305th of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 27th largest by planned enrollment of the 74 observational ones that give a count, is one of 41 that started in 2025, is one of 74 observational ones, reaches primary completion later than 65 of the 137 other live ones, and was the 305th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

113 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

Post-stroke depression (PSD) is the most common neuropsychiatric disorder after a stroke, with an incidence rate of 20% to 60%. PSD is not only associated with higher mortality rates, poorer recovery, more obvious cognitive impairments, greater economic burdens, and lower quality of life, but also brings additional medical expenses and care pressure to families. Society also needs to bear higher medical costs. Currently, the early diagnosis of PSD is difficult, which may lead to poor prognosis after stroke. This study aims to utilize machine learning technology to integrate multi-dimensional indicators of patients with ischemic stroke, establish a risk prediction model for PSD, and assist in early, accurate, and individualized assessment of PSD risk in clinical practice.

03

Conditions studied

  • Post-stroke Depression
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Acute ischemic stroke patients who may develop post-stroke depression

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute ischemic stroke;
  • Admission within 7 days of symptom onset;
  • The patient and/or the family members sign a written form.

Exclusion criteria

Exclusion Criteria:

  • Confusion of consciousness,severe cognitive impairment, etc
  • Individuals with a history of depression, schizophrenia, bipolar disorder, etc;
  • Individuals unable to participate in neuropsychological examinations due to hearing im pairments, lack of coordination, or neurological deficits, including se vere aphasia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
488 participants (estimated)
Patient registry
No

Groups and cohorts

  • The group of PSD

    The patient was diagnosed with PSD.

    Diagnostic Test: Group patients based on whether they have been diagnosed with PSD.

  • NPSD

    The patient was not diagnosed with PSD.

    Diagnostic Test: Group patients based on whether they have been diagnosed with PSD.

Interventions

  • Diagnostic testGroup patients based on whether they have been diagnosed with PSD.

    Group patients based on whether they have been diagnosed with PSD.

06

What researchers measure

Primary outcomes

  1. The number of post-stroke depression (PSD) that occurs 3 months after stroke

    Time frame: 3 months after stroke

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2026, 8 months after the start.

Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 8 months is below that.

Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 19, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Jul 20, 2026
CompletionEst.
Jul 20, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07294274
Lead sponsor
Min Su
Collaborators
Chongqing Traditional Chinese Medicine Hospital
Responsible party
Min Su (Professor of Anesthesiology, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Dec 19, 2025
Start date
Nov 1, 2025
Primary completion
Jul 20, 2026 (estimated)
Completion
Jul 20, 2026 (estimated)
Last update
Feb 5, 2026

Study contacts

Yanping Zhang
Contact
zhangyp8415@163.com
86+15223049366

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion